Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of its in-vivo candidate, CTX310, as well as better-than-expected sales of ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within the hematology community: whether the future ...

Net Loss: BioXcel Therapeutics an operating loss of $15.9 million and a net loss of $19.2 million for the second quarter of 2025, compared to an operating loss of $17.3 million and net loss of $8.3 ...

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.